Telazorlimab

DB16374InvestigationalProtein Based Therapies

Telazorlimab is under investigation in clinical trial NCT03568162 (Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 4
Curator reviewed
Code names: GBR-830 · ISB-830

Resolves to

Compound

UNII0CRN540O4RCAS2126777-87-3

Targets

P43489TNFRSF4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telazorlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account